Premium
Carboplatin Hypersensitivity Reactions in Pediatric Low Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy
Author(s) -
Dodgshun Andrew J.,
Hansford Jordan R.,
Cole Theresa,
Choo Sharon,
Sullivan Michael J.
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25686
Subject(s) - medicine , carboplatin , desensitization (medicine) , blood cancer , glioma , hypersensitivity reaction , dosing , oncology , pharmacology , chemotherapy , cisplatin , cancer research , cancer , receptor
Background The use of carboplatin for the treatment of pediatric low grade gliomas (PLGG) is often limited by the development of carboplatin hypersensitivity. Reported rates of carboplatin hypersensitivity reactions vary between 6% and 32% in these patients. Here we report the frequency of carboplatin hypersensitivity reactions depending on the treatment regimen used, and outcomes of carboplatin desensitization. Methods The records of all patients in a single institution who were treated with carboplatin for PLGG were accessed and all patients receiving more than one dose of carboplatin are reported. Results Thirty four patients with PLGG were treated with carboplatin according to one of the two different regimens. Carboplatin hypersensitivity was documented in 47% of patients, but the frequency differed by treatment protocol. Those patients treated with 4‐weekly single agent carboplatin had carboplatin allergy in 8% of cases whereas 68% of those treated with combined carboplatin and vincristine (every three weeks, according to the SIOP 2004 low grade glioma protocol) had carboplatin reactions (OR 23.6, P < 0.01). Desensitization was only successful in two out of 10 patients in whom it was attempted. Conclusions Hypersensitivity reactions to carboplatin are more common in this cohort than previously reported and rates are protocol‐dependent. Desensitization showed limited effectiveness in this cohort. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.